MedTrace Logo

Novel MRI Biomarkers for Monitoring Disease Progression in ALS

NCT03362658 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 119

Last updated 2026-05-08

No results posted yet for this study

Summary

Routine MRI is normal in motor neuron diseases such as ALS. However, advanced MRI techniques can provide an objective measure of degeneration (a "biomarker") by examining brain structure, wiring, chemistry, and function. We will develop and evaluate novel MRI techniques that could improve our understanding of ALS and provide a means to diagnose it sooner and monitor its progression. Importantly, we expect these techniques to improve how new drugs are tested, which may lead to the more rapid discovery of a treatment for ALS.

Each participant will have 3 MRI scans over a period of 8 months, along with neurological and cognitive evaluations. Study visits will take 2 - 3 hours. MRI is a safe technique that does not involve radiation.

Conditions

Sponsors & Collaborators

  • University of Calgary

    collaborator OTHER

  • Western University, Canada

    collaborator OTHER

  • McGill University

    collaborator OTHER

  • University of Toronto

    collaborator OTHER

  • University of British Columbia

    collaborator OTHER

  • Laval University

    collaborator OTHER

  • University of Miami

    collaborator OTHER

  • University of Utah

    collaborator OTHER

  • University of Alberta

    lead OTHER

Principal Investigators

  • Sanjay Kalra, MD · FRCPC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2023-12-31
Completion
2026-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03362658 on ClinicalTrials.gov